Clinical Trials
11 trialsNCT05415917 2026-05-07
Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT02872831 2026-04-13
Beacon BNXâ„¢ Endoscopic Ultrasound (EUS)-Needle vs SharkCoreâ„¢ Needle
Thomas Jefferson University
Phase NA Withdrawn
NCT05188573 2026-03-27
EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients
ClearNote Health
Phase NA Withdrawn
NCT05360745 2026-02-11
FOODPANC
Fundacion para la Excelencia y la Calidad de la Oncologia
Phase NA Withdrawn
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT07026916 2025-11-17
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 2 Withdrawn
NCT06690281 2025-09-11
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT05737615 2025-09-04
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT05634525 2025-07-25
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT06498518 2025-07-11
PRIMUS006
University of Glasgow
Phase 2 Withdrawn
NCT06545344 2025-06-29
Palliative Care Consultation to Improve Communication for Patients Considering Surgery for a Pancreatic Neoplasm
Fred Hutchinson Cancer Center
Phase NA Withdrawn